Summary
Should You Buy Si-Bone (SIBN) After Golden Cross?
After reaching an important support level, SiBone (SIBN) could be a good stock pick from a technical perspective. SIBN recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
SI-BONE, Inc. (SIBN) Q3 2025 Earnings Call Transcript
SI-BONE, Inc. ( SIBN ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Saqib Iqbal - Director of FP&A and Investor Relations Laura Francis - CEO & Director Anshul Maheshwari - Chief Financial Officer Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Caitlin Cronin - Canaccord Genuity Corp., Research Division Matthew O'Brien - Piper Sandler & Co., Research Division Gracia Mahoney - BofA Securities, Research Division Young Li - Jefferies LLC, Research Division Ross Osborn - Cantor Fitzgerald & Co., Research Division David Saxon - Needham & Company, LLC, Research Division Ravi Misra - Truist Securities, Inc., Research Division Presentation Operator Good afternoon, and welcome to SI-BONE's Third Quarter 2025 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes.
Si-Bone (SIBN) Reports Q3 Loss, Beats Revenue Estimates
Si-Bone (SIBN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.16 per share a year ago.
Si-Bone Inc. (SIBN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Si-Bone Inc. ever had a stock split?
Si-Bone Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Laura A. Francis MBA CEO | NASDAQ (NMS) Exchange | 825704109 CUSIP |
| US Country | 349 Employees | - Last Dividend | - Last Split | 17 Oct 2018 IPO Date |
Overview
SI-BONE, Inc. is a pioneering medical device company focused on tackling musculoskeletal disorders specifically related to the sacropelvic anatomy. With operations extending across the United States and internationally, SI-BONE aims to bring innovative solutions to common but complex problems such as sacroiliac joint dysfunction, adult spinal deformities, degeneration, and pelvic trauma through its minimally invasive surgical implant systems. Since its inception in 2008, the company has been at the forefront of medical device technology, building a name for itself in the industry. Headquartered in Santa Clara, California, SI-BONE has dedicated itself to improving patient outcomes while reducing recovery times, leveraging a combination of advanced technology and clinical understanding to meet the needs of patients and healthcare providers alike.
Products and Services
- iFuse-3D
A revolutionary titanium implant that epitomizes the fusion of form and function. The iFuse-3D has been uniquely designed, incorporating a triangular cross-section with a 3D-printed porous surface to enhance osseointegration, along with a fenestrated design to allow for bone in-growth. This product is specifically engineered to address sacroiliac joint dysfunction, offering patients a potentially faster recovery and improved surgical outcomes.
- iFuse-TORQ
Specifically designed for the treatment of pelvic trauma, the iFuse-TORQ represents a leap in implant technology. These 3D-printed threaded implants are meticulously crafted to promote healing in the pelvic region following traumatic injury. The innovative design aims to provide stable fixation during the critical healing period, demonstrating SI-BONE’s commitment to addressing complex pelvic injuries through state-of-the-art solutions.
- iFuse Bedrock Granite
The iFuse Bedrock Granite implant sets a new standard for sacroiliac fusion and sacropelvic fixation. Intended as a foundational element for segmental spinal fusion, this product underscores the importance of a stable sacropelvic region in overall spinal health. Its design focuses on creating a reliable base for further spinal fusion procedures, thereby enhancing the stability and success rates of complex spinal surgeries.
Contact Information
